News & Updates
Filter by Specialty:
Pembrolizumab extends RFS in stage II melanoma
01 Nov 2021
byRoshini Claire Anthony
Pembrolizumab extended recurrence-free survival (RFS) in patients with high-risk stage II melanoma who had undergone complete resection, interim analysis results of the phase III KEYNOTE-716 trial showed.
Pembrolizumab extends RFS in stage II melanoma
01 Nov 2021Sustained benefit with anti-TNFα less likely to lead to subsequent loss of response in IBD
01 Nov 2021
Inflammatory bowel disease (IBD) patients receiving treatment with antitumour necrosis factor alpha (anti-TNFα) for more than 2 years represent a distinct group who obtain prolonged clinical benefit and tolerate maintenance treatment, according to a study.
Sustained benefit with anti-TNFα less likely to lead to subsequent loss of response in IBD
01 Nov 2021Post-ICH antiplatelet therapy not linked to recurrent ICH
28 Oct 2021
byRoshini Claire Anthony
Initiating antiplatelet therapy following an intracerebral haemorrhage (ICH) that occurred during antithrombotic use does not lead to recurrent symptomatic ICH, according to extended results of the RESTART* trial.